Hyperkalemia risk in chronic kidney disease deterrent to the use of aldosterone receptor antagonism or not

Hypertension

Volumn 53, Issue 5, 2009, Pages 749-750

  Sica, Domenic A ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; MINERALOCORTICOID ANTAGONIST; POTASSIUM; RENIN INHIBITOR; SPIRONOLACTONE;

BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; COST EFFECTIVENESS ANALYSIS; DIALYSIS; DRUG SAFETY; HEALTH CARE COST; HUMAN; HYPERKALEMIA; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; NOTE; POTASSIUM BLOOD LEVEL; POTASSIUM EXCRETION; POTASSIUM RESTRICTION; PRIORITY JOURNAL; PROTEINURIA; RISK ASSESSMENT; SALT INTAKE; SCREENING;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; CHRONIC DISEASE; HUMANS; HYPERKALEMIA; KIDNEY DISEASES; RECEPTORS, ALDOSTERONE;

EID: 73549091271     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.108.128017     Document Type: Note

References (10)

1. Grassmann A, Gioberge S, Moeller S, Brown G. ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends. Nephrol Dial Transplant. 2005;20:2587-2593.
2. Whaley-Connell AT, Sowers JR, Stevens LA, McFarlane SI, Shlipak MG, Norris KC, Chen SC, Qiu Y, Wang C, Li S, Vassalotti JA, Collins AJ. Kidney Early Evaluation Program Investigators. Am J Kidney Dis. 2008;51(suppl 2):S13-S20.
3. Wenzel U. Aldosterone and progression of renal disease. Curr Opin Nephrol Hypertens. 2008;17:44-50.
4. Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol. 2007;3:486-492.
5. Bomback AS, Kshirsagar AV, Amamoo MA, Klemmer PJ. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis. 2008;51:199-211.
6. Tylicki L, Rutkowski P, Renke M, Larczyński W, Aleksandrowicz E, Lysiak-Szydlowska W, Rutkowski B. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. Am J Kidney Dis 2008; 52:486-493.
7. 7. Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int. 2006;70:2116-2123. (Pubitemid 44871374)
8. 8. Sica DA. The risks and benefits of therapy with aldosterone receptor antagonist therapy. Curr Drug Saf. 2007;2:71-77. (Pubitemid 46723171)
9. Sica DA. Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Fail Rev. 2005;10:23-29.
10. Preston RA, Afshartous D, Garg D, Medrano S, Alonso AB, Rodriguez R. Mechanisms of impaired potassium handling with dual renin-angiotensin- aldosterone blockade in chronic kidney disease. Hypertension. 2009; 53:754-760.